Chemexpress(SH:688131) Xin Lang Cai Jing·2025-11-06 07:07Core Insights - Haoyuan Pharmaceutical experienced a 5.2% increase in stock price, reaching 78.51 CNY per share, with a trading volume of 313 million CNY and a turnover rate of 1.94%, resulting in a total market capitalization of 16.652 billion CNY [1] Company Overview - Shanghai Haoyuan Pharmaceutical Co., Ltd. was established on September 30, 2006, and went public on June 8, 2021. The company specializes in the discovery of small molecule drugs, focusing on molecular building blocks and tool compounds, as well as the development and production of active pharmaceutical ingredients (APIs) and intermediates [1] - The main business revenue composition includes molecular building blocks, tool compounds, and biochemical reagents at 68.97%, with product sales contributing 63.42%, APIs and intermediates at 30.46%, technical services at 5.55%, and other supplementary services at 0.57% [1] Fund Holdings - According to data, one fund under GF Fund has a significant holding in Haoyuan Pharmaceutical. The GF Medical Selected Stock A (017479) held 39,000 shares in the third quarter, accounting for 5.25% of the fund's net value, ranking as the eighth largest holding [2] - The GF Medical Selected Stock A (017479) was established on July 6, 2023, with a latest scale of 41.6154 million CNY. Year-to-date returns stand at 44.25%, ranking 797 out of 4216 in its category, while the one-year return is 37.56%, ranking 854 out of 3909 [2] Fund Manager Profile - The fund manager of GF Medical Selected Stock A (017479) is Wang Ruidong, who has been in the position for 5 years and 172 days. The total asset scale of the fund is 4.817 billion CNY, with the best fund return during his tenure being 59.03% and the worst at -12.32% [3]